Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPHYF Innate Pharma	$2.06	$1.62	$1.31 ▼ $2.06	$172.65M	0.47	15 shs	N/A
KALV KalVista Pharmaceuticals	$12.96 +0.4%	$13.40	$7.30 ▼ $16.32	$647.35M	0.05	784,879 shs	396,887 shs
RIGL Rigel Pharmaceuticals	$41.99 +1.5%	$23.28	$12.00 ▼ $42.80	$753.30M	1.21	296,141 shs	1.05 million shs
SIGA Siga Technologies	$8.75 -0.3%	$7.11	$4.95 ▼ $9.80	$626.59M	0.94	476,107 shs	471,392 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPHYF Innate Pharma	0.00%	0.00%	+57.21%	+42.03%	-1.93%
KALV KalVista Pharmaceuticals	+0.78%	+2.54%	-17.03%	+13.05%	+3.16%
RIGL Rigel Pharmaceuticals	+6.21%	+13.07%	+111.13%	+109.63%	+230.35%
SIGA Siga Technologies	+0.11%	0.00%	+28.18%	+50.34%	-0.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IPHYF Innate Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	3.9955 of 5 stars	3.6	1.0	0.0	4.4	2.6	1.7	0.6
RIGL Rigel Pharmaceuticals	1.6766 of 5 stars	1.2	1.0	0.0	0.0	2.5	1.7	3.1
SIGA Siga Technologies	2.0794 of 5 stars	0.0	2.0	0.0	0.0	2.4	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IPHYF Innate Pharma	0.00	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	102.82% Upside
RIGL Rigel Pharmaceuticals	2.40	Hold	$38.20	-9.03% Downside
SIGA Siga Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IPHYF, RIGL, KALV, and SIGA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	RIGL Rigel Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $32.00
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IPHYF Innate Pharma	$21.77M	7.93	N/A	N/A	$0.11 per share	18.72
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A
RIGL Rigel Pharmaceuticals	$179.28M	4.20	$1.16 per share	36.09	$4.57 per share	9.19
SIGA Siga Technologies	$138.72M	4.52	$0.83 per share	10.48	$2.92 per share	3.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IPHYF Innate Pharma	-$53.53M	N/A	0.00	∞	N/A	N/A	N/A	N/A	9/17/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)
RIGL Rigel Pharmaceuticals	$17.49M	$5.41	7.76	39.99	N/A	36.51%	438.89%	57.03%	11/6/2025 (Estimated)
SIGA Siga Technologies	$59.21M	$1.13	7.74	7.00	N/A	45.73%	40.52%	35.62%	11/6/2025 (Estimated)

Latest IPHYF, RIGL, KALV, and SIGA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2025	Q1 2026	KALV KalVista Pharmaceuticals	-$0.91	N/A	N/A	N/A	$1.97 million	N/A
8/5/2025	Q2 2025	RIGL Rigel Pharmaceuticals	$1.97	$3.28	+$1.31	$3.28	$64.58 million	$101.69 million
8/5/2025	Q2 2025	SIGA Siga Technologies	N/A	$0.49	N/A	$0.49	N/A	$81.12 million
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IPHYF Innate Pharma	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RIGL Rigel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SIGA Siga Technologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IPHYF Innate Pharma	N/A	2.60	2.60
KALV KalVista Pharmaceuticals	N/A	5.35	5.35
RIGL Rigel Pharmaceuticals	0.46	2.02	1.90
SIGA Siga Technologies	N/A	10.09	8.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IPHYF Innate Pharma	N/A
KALV KalVista Pharmaceuticals	N/A
RIGL Rigel Pharmaceuticals	66.23%
SIGA Siga Technologies	55.40%

Insider Ownership

Company	Insider Ownership
IPHYF Innate Pharma	31.89%
KALV KalVista Pharmaceuticals	10.50%
RIGL Rigel Pharmaceuticals	9.48%
SIGA Siga Technologies	1.95%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IPHYF Innate Pharma	179	83.83 million	57.10 million	Not Optionable
KALV KalVista Pharmaceuticals	100	49.95 million	44.71 million	Optionable
RIGL Rigel Pharmaceuticals	160	17.94 million	16.24 million	Optionable
SIGA Siga Technologies	40	71.61 million	70.21 million	Optionable

IPHYF, RIGL, KALV, and SIGA Headlines

Recent News About These Companies

First Wilshire Securities Management Inc. Has $8.70 Million Stock Position in Siga Technologies Inc. $SIGA

August 21 at 6:06 AM | marketbeat.com

SIGA Technologies: Still Bullish, But Worth Trimming Ahead Of BARDA News

August 20 at 3:04 AM | seekingalpha.com

Siga Technologies (NASDAQ:SIGA) Trading Down 4.9% - Should You Sell?

August 15, 2025 | marketbeat.com

Siga Technologies (NASDAQ:SIGA) Rating Increased to Strong-Buy at Wall Street Zen

August 11, 2025 | americanbankingnews.com

Wall Street Zen Upgrades Siga Technologies (NASDAQ:SIGA) to Strong-Buy

August 10, 2025 | marketbeat.com

SIGA Technologies Second Quarter 2025 Earnings: EPS: US$0.50 (vs US$0.026 in 2Q 2024)

August 8, 2025 | finance.yahoo.com

Siga Technologies (NASDAQ:SIGA) Trading 13.9% Higher - Here's Why

August 7, 2025 | marketbeat.com

SIGA (SIGA) Q2 Revenue Soars 272%

August 7, 2025 | theglobeandmail.com

Siga Technologies (NASDAQ:SIGA) Issues Earnings Results

August 6, 2025 | marketbeat.com

SIGA Technologies (SIGA) Reports Significant Earnings Decline

August 6, 2025 | finance.yahoo.com

SIGA advances pediatric and PEP programs as product revenues reach $79M, supported by new BARDA funding

August 6, 2025 | msn.com

SIGA Technologies, Inc. (SIGA) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

SIGA Reports Financial Results for Three and Six Months Ended June 30, 2025

August 5, 2025 | globenewswire.com

SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results

July 29, 2025 | globenewswire.com

Royce & Associates LP Has $4.16 Million Holdings in Siga Technologies Inc. (NASDAQ:SIGA)

July 28, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Stock Falls Amid Market Uptick: What Investors Need to Know

July 24, 2025 | zacks.com

Traders Buy Large Volume of Call Options on Siga Technologies (NASDAQ:SIGA)

July 24, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Dips More Than Broader Market: What You Should Know

July 15, 2025 | msn.com

US Market's Undiscovered Gems Featuring Three Promising Small Caps

July 15, 2025 | finance.yahoo.com

Siga Technologies Inc. (SIGA) Laps the Stock Market: Here's Why

July 9, 2025 | zacks.com

SIGA Technologies Inc Dividends - Morningstar

July 8, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHYF, RIGL, KALV, and SIGA Company Descriptions

Innate Pharma OTCMKTS:IPHYF

$2.06 0.00 (0.00%)

As of 08/18/2025

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

KalVista Pharmaceuticals NASDAQ:KALV

$12.96 +0.05 (+0.39%)

Closing price 04:00 PM Eastern

Extended Trading

$12.96 0.00 (0.00%)

As of 07:15 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Rigel Pharmaceuticals NASDAQ:RIGL

$41.99 +0.63 (+1.52%)

Closing price 04:00 PM Eastern

Extended Trading

$41.45 -0.54 (-1.29%)

As of 07:40 PM Eastern

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.

Siga Technologies NASDAQ:SIGA

$8.75 -0.03 (-0.34%)

Closing price 04:00 PM Eastern

Extended Trading

$8.75 0.00 (0.00%)

As of 07:08 PM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time